Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
In recent years, research on immunotherapy has made great progress. Currently, immunotherapy has made significant breakthrough, especially programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors (e.g, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab and Avelumab, etc.) have...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2019-06-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.06.07 |
| _version_ | 1828434475304878080 |
|---|---|
| author | Di ZHANG Jiaqi HUANG Chufeng ZHANG Yan GUAN Qisen GUO |
| author_facet | Di ZHANG Jiaqi HUANG Chufeng ZHANG Yan GUAN Qisen GUO |
| author_sort | Di ZHANG |
| collection | DOAJ |
| description | In recent years, research on immunotherapy has made great progress. Currently, immunotherapy has made significant breakthrough, especially programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors (e.g, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab and Avelumab, etc.) have brought clinical benefits to patients with various pathological types of lung cancer, including squamous cell carcinoma, adenocarcinoma and small cell lung cancer. In this paper, the application value and current status of PD-1/PD-L1 checkpoint inhibitors in lung cancer were comprehensively analyzed by reviewing and interpreting representative clinical studies. Based on the results of various large-scale clinical trials results, the indications of immunotherapy in lung cancer have been continuously broadened, and the details of immunotherapy have also been constantly optimized. However, immunotherapy still faces many challenges, such as the selection of immune combination strategies, the exploration of biomarkers, the management of adverse events, the feasibility of application of driver gene mutation population and so on. In this article, we made a systematic review about the latest progress of PD-1/PD-L1 checkpoint inhibitors in lung cancer, in order to provide cutting-edge reference for the clinical workers. |
| first_indexed | 2024-12-10T18:51:44Z |
| format | Article |
| id | doaj.art-62b31c06c4fc4e60b02a8d10c68082a9 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-10T18:51:44Z |
| publishDate | 2019-06-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-62b31c06c4fc4e60b02a8d10c68082a92022-12-22T01:37:18ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872019-06-0122636937910.3779/j.issn.1009-3419.2019.06.07Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung CancerDi ZHANG0Jiaqi HUANG1Chufeng ZHANG2Yan GUAN3Qisen GUO4Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong University, Jinan 250100, ChinaDepartment of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong University, Jinan 250100, ChinaDepartment of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan 250117, ChinaDepartment of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan 250117, ChinaDepartment of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan 250117, ChinaIn recent years, research on immunotherapy has made great progress. Currently, immunotherapy has made significant breakthrough, especially programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors (e.g, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab and Avelumab, etc.) have brought clinical benefits to patients with various pathological types of lung cancer, including squamous cell carcinoma, adenocarcinoma and small cell lung cancer. In this paper, the application value and current status of PD-1/PD-L1 checkpoint inhibitors in lung cancer were comprehensively analyzed by reviewing and interpreting representative clinical studies. Based on the results of various large-scale clinical trials results, the indications of immunotherapy in lung cancer have been continuously broadened, and the details of immunotherapy have also been constantly optimized. However, immunotherapy still faces many challenges, such as the selection of immune combination strategies, the exploration of biomarkers, the management of adverse events, the feasibility of application of driver gene mutation population and so on. In this article, we made a systematic review about the latest progress of PD-1/PD-L1 checkpoint inhibitors in lung cancer, in order to provide cutting-edge reference for the clinical workers.http://dx.doi.org/10.3779/j.issn.1009-3419.2019.06.07Programmed death 1Programmed death-ligand 1Immune checkpoint inhibitorsImmunotherapyLung neoplasms |
| spellingShingle | Di ZHANG Jiaqi HUANG Chufeng ZHANG Yan GUAN Qisen GUO Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer Chinese Journal of Lung Cancer Programmed death 1 Programmed death-ligand 1 Immune checkpoint inhibitors Immunotherapy Lung neoplasms |
| title | Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer |
| title_full | Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer |
| title_fullStr | Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer |
| title_full_unstemmed | Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer |
| title_short | Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer |
| title_sort | progress on pd 1 pd l1 checkpoint inhibitors in lung cancer |
| topic | Programmed death 1 Programmed death-ligand 1 Immune checkpoint inhibitors Immunotherapy Lung neoplasms |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.06.07 |
| work_keys_str_mv | AT dizhang progressonpd1pdl1checkpointinhibitorsinlungcancer AT jiaqihuang progressonpd1pdl1checkpointinhibitorsinlungcancer AT chufengzhang progressonpd1pdl1checkpointinhibitorsinlungcancer AT yanguan progressonpd1pdl1checkpointinhibitorsinlungcancer AT qisenguo progressonpd1pdl1checkpointinhibitorsinlungcancer |